Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Atezolizumab + Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin |
Indication/Tumor Type | ovary epithelial cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | ovary epithelial cancer | no benefit | Atezolizumab + Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin | Phase III | Actionable | In a Phase III trial (ATALANTE/ENGOT-ov29), Avastin (bevacizumab) combined with platinum-based chemotherapy (carboplatin plus gemcitabine, doxil, or paclitaxel) plus Tecentriq (atezolizumab) vs placebo did not meet the primary progression-free survival (PFS) objective in CD274 (PD-L1)-positive epithelial ovarian cancer patients, with a median PFS of 15.2 vs 13.1 mo (HR=0.86, P=0.30), and resulted in a median overall survival of 40.7 vs 33.6 mo (HR=0.90), respectively (PMID: 37643382; NCT02891824). | 37643382 |
PubMed Id | Reference Title | Details |
---|---|---|
(37643382) | Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. | Full reference... |